1209 related articles for article (PubMed ID: 27806234)
1. Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway.
Boussiotis VA
N Engl J Med; 2016 Nov; 375(18):1767-1778. PubMed ID: 27806234
[No Abstract] [Full Text] [Related]
2. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.
Meng X; Huang Z; Teng F; Xing L; Yu J
Cancer Treat Rev; 2015 Dec; 41(10):868-76. PubMed ID: 26589760
[TBL] [Abstract][Full Text] [Related]
3. The immunosuppressive ligands PD-L1 and CD200 are linked in AML T-cell immunosuppression: identification of a new immunotherapeutic synapse.
Coles SJ; Gilmour MN; Reid R; Knapper S; Burnett AK; Man S; Tonks A; Darley RL
Leukemia; 2015 Sep; 29(9):1952-4. PubMed ID: 25748687
[No Abstract] [Full Text] [Related]
4. The PD-1/PD-L1 pathway: biological background and clinical relevance of an emerging treatment target in immunotherapy.
Muenst S; Soysal SD; Tzankov A; Hoeller S
Expert Opin Ther Targets; 2015 Feb; 19(2):201-11. PubMed ID: 25491730
[TBL] [Abstract][Full Text] [Related]
5. Checkpoint inhibitors for cancer immunotherapy. Multiple checkpoints on the long road towards cancer immunotherapy.
Phan TG; Long GV; Scolyer RA
Immunol Cell Biol; 2015 Apr; 93(4):323-5. PubMed ID: 25686808
[No Abstract] [Full Text] [Related]
6. [The Role of PD-1/PD-L1 Signaling Pathway in Antitumor Immune Response].
Zatloukalová P; Pjechová M; Babčanová S; Hupp TR; Vojtěšek B
Klin Onkol; 2016; 29 Suppl 4(Suppl 4):72-77. PubMed ID: 27846724
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.
Philips GK; Atkins M
Int Immunol; 2015 Jan; 27(1):39-46. PubMed ID: 25323844
[TBL] [Abstract][Full Text] [Related]
8. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.
Massari F; Santoni M; Ciccarese C; Santini D; Alfieri S; Martignoni G; Brunelli M; Piva F; Berardi R; Montironi R; Porta C; Cascinu S; Tortora G
Cancer Treat Rev; 2015 Feb; 41(2):114-21. PubMed ID: 25586601
[TBL] [Abstract][Full Text] [Related]
9. Viral Infection of Tumors Overcomes Resistance to PD-1-immunotherapy by Broadening Neoantigenome-directed T-cell Responses.
Woller N; Gürlevik E; Fleischmann-Mundt B; Schumacher A; Knocke S; Kloos AM; Saborowski M; Geffers R; Manns MP; Wirth TC; Kubicka S; Kühnel F
Mol Ther; 2015 Oct; 23(10):1630-40. PubMed ID: 26112079
[TBL] [Abstract][Full Text] [Related]
10. Primary and acquired resistance to PD-1/PD-L1 blockade in cancer treatment.
Wang Q; Wu X
Int Immunopharmacol; 2017 May; 46():210-219. PubMed ID: 28324831
[TBL] [Abstract][Full Text] [Related]
11. PD-L1 inhibition with MPDL3280A for solid tumors.
Cha E; Wallin J; Kowanetz M
Semin Oncol; 2015 Jun; 42(3):484-7. PubMed ID: 25965367
[TBL] [Abstract][Full Text] [Related]
12. Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases.
Harter PN; Bernatz S; Scholz A; Zeiner PS; Zinke J; Kiyose M; Blasel S; Beschorner R; Senft C; Bender B; Ronellenfitsch MW; Wikman H; Glatzel M; Meinhardt M; Juratli TA; Steinbach JP; Plate KH; Wischhusen J; Weide B; Mittelbronn M
Oncotarget; 2015 Dec; 6(38):40836-49. PubMed ID: 26517811
[TBL] [Abstract][Full Text] [Related]
13. Immunobiology of cancer therapies targeting CD137 and B7-H1/PD-1 cosignal pathways.
Wang S; Chen L
Curr Top Microbiol Immunol; 2011; 344():245-67. PubMed ID: 20582531
[TBL] [Abstract][Full Text] [Related]
14. Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy.
Hamid O; Carvajal RD
Expert Opin Biol Ther; 2013 Jun; 13(6):847-61. PubMed ID: 23421934
[TBL] [Abstract][Full Text] [Related]
15. Overcoming T cell exhaustion in infection and cancer.
Pauken KE; Wherry EJ
Trends Immunol; 2015 Apr; 36(4):265-76. PubMed ID: 25797516
[TBL] [Abstract][Full Text] [Related]
16. MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade.
Ebert PJR; Cheung J; Yang Y; McNamara E; Hong R; Moskalenko M; Gould SE; Maecker H; Irving BA; Kim JM; Belvin M; Mellman I
Immunity; 2016 Mar; 44(3):609-621. PubMed ID: 26944201
[TBL] [Abstract][Full Text] [Related]
17. Targeting immune checkpoints in lymphoma.
Ansell SM
Curr Opin Hematol; 2015 Jul; 22(4):337-42. PubMed ID: 26049755
[TBL] [Abstract][Full Text] [Related]
18. Checkpoint blocking antibodies in cancer immunotherapy.
Kyi C; Postow MA
FEBS Lett; 2014 Jan; 588(2):368-76. PubMed ID: 24161671
[TBL] [Abstract][Full Text] [Related]
19. Study May Change Approach to Immunotherapy.
Cancer Discov; 2016 May; 6(5):OF1. PubMed ID: 27012834
[TBL] [Abstract][Full Text] [Related]
20. Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities.
Merelli B; Massi D; Cattaneo L; Mandalà M
Crit Rev Oncol Hematol; 2014 Jan; 89(1):140-65. PubMed ID: 24029602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
